Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma

Seminars in Oncology

Volumn 32, Issue SUPPL. 1, 2005, Pages 36-43

  Marcus, Robert ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RECOMBINANT INTERFERON; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ABDOMINAL PAIN; ANEMIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; COVALENT BOND; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSPNEA; ECCHYMOSIS; FEBRILE NEUTROPENIA; FLUSHING; FOLLOW UP; HAIR LOSS; HEADACHE; HUMAN; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; SIDE EFFECT; THROAT DISEASE; THROMBOCYTOPENIA; WHOLE BODY RADIATION; ARTICLE; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 15744381025     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.01.012     Document Type: Conference Paper

References (28)

1. L.A.G. Ries, M.P. Eisner, C.L. Kosary SEER Cancer Statistics Review, 1973-1999 2002 National Cancer Institute Bethesda, MD
2. R.I. Fisher, E.R. Gaynor, S. Dahlberg Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1993 1002 1006
3. P. Solal-Celigny, E. Lepage, N. Brousse Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial J Clin Oncol 16 1998 2332 2338
4. P. Colombat, G. Salles, N. Brousse Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden Clinical and molecular evaluation Blood 97 2001 101 106
5. J.D. Hainsworth, H.A. Burris III, L.H. Morrissey Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma Blood 95 2000 3052 3056
6. J.D. Hainsworth, S. Litchy, H.A. Burris Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma J Clin Oncol 20 2002 4261 4267
7. M.S. Czuczman, R. Weaver, B. Alkuzweny Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy 9-Year follow-up J Clin Oncol 22 2004 4659 4664
8. W. Hiddemann, M. Dreyling, M. Unterhalt Rituximab plus chemotherapy in follicular and mantle cell lymphomas Semin Oncol 30 suppl 2 2003 16 20
9. B. Coiffier, E. Lepage, J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
10. M.S. Cragg, S.M. Morgan, H.T. Claude Chan Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood 101 2003 1045 1052
11. H.N. Wagner, G.A. Wiseman, C.S. Marcus Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody J Nucl Med 43 2002 267 272
12. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma Combined data from 4 clinical trials J Nucl Med 44 2003 465 474
13. + B-cell non-Hodgkin's lymphoma J Clin Oncol 17 1999 3793 3803
14. T.E. Witzig, I.W. Flinn, L.I. Gordon Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
15. L.I. Gordon, T.E. Witzig, J.L. Murray Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL Final results of a randomized controlled trial Proc Am Soc Clin Oncol 22 2003 576 (abstr)
16. G.A. Wiseman, L.I. Gordon, P.S. Multani Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia A phase II multicenter trial Blood 99 2002 4336 4342
17. T.E. Witzig, L.I. Gordon, F. Cabanillas Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol 20 2002 3262 3269
18. L.I. Gordon, A. Molina, T.E. Witzig Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma Long term follow-up of a phase I/II study Blood 103 2004 4429 4431
19. T.E. Witzig, A. Molina, L.I. Gordon Yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy induces durable remission sin patients with relapsed or refractory B-cell non-Hodgkin's lymphoma Analysis of long-term responders Blood 102 2003 407a (abstr)
20. T.E. Witzig, C.A. White, L.I. Gordon Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma J Clin Oncol 21 2003 1263 1270
21. C. Nabhan, L.A. Peterson, S.A. Kent Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma Leuk Lymph 43 2002 2145 2149
22. M. Czuczman, T.E. Witzig, I. Gaston Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) Blood 100 2002 357a (abstr)
23. S.M. Ansell, K.M. Ristow, T.M. Habermann Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma J Clin Oncol 20 2002 3885 3890
24. R.J. Schilder, T.E. Witzig, L. Gordon 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma Proc Am Soc Clin Oncol 21 2002 267a (abstr)
25. J.A. Radford, N. Ketterer, C. Sebban Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission Interim analysis for safety of a multicenter, phase III clinical trial Blood 102 2003 408a (abstr)
26. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients Proc Am Soc Clin Oncol 21 2002 14a (abstr)
27. A. Nadamanee, A. Molina, S.J. Forman A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL) Blood 100 2002 182a (abstr)
28. J.N. Winter, D. Inwards, W. Erwin Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma Early outcome results Blood 100 2002 411a (abstr)